drugset
drugset / Trial / NCT00209937

A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia

NCT00209937 ↗

Phase 3 Completed 675 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia

Timeline

Start
2003-01
Primary completion
—
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gaboxadol Unknown — —

Indications

insomnia